NGEN · NervGen Pharma
AI read · Good for NGEN
The AI's read
The cash reserve is expected to cover the company until the study reports, reducing pressure to find more funding beforehand. The FDA designation also points to promise in earlier study results. The main limit is timing: the new study results are not expected until the first half of 2028.